A Phase 4 interventional study of Avatrombopag Oral Tablet in Immune Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.
Sponsored by Sobi, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 2 in phase 4, and was the 9th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 6–18
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18+
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 53 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Sobi, Inc., one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Sobi, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Swedish Orphan Biovitrum has 5 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
This Phase 4, prospective, multi-center, open-label study will evaluate safety, platelet count, and subject reported medication satisfaction in adult subjects with chronic ITP after switching to avatrombopag from eltrombopag or romiplostim. At least 100 subjects will be enrolled, 50 (±10) who have received eltrombopag and 50 (±10) who have received romiplostim for at least 90 days prior to study entry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Avatrombopag 20 mg oral tablet formulation for 90 days
Drug: Avatrombopag Oral Tablet
Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
Also known as: Doptelet
Safety and Tolerability (Adverse Events)
Safety and Tolerability of Avatrombopag given for 90 days after stopping eltrombopag or romiplostim The incidence and severity of adverse events (AEs), serious adverse events (SAE) and adverse events of special interest (AESIs) will be summarized for all enrolled subjects using counts and percentages. Treatment-emergent AEs and SAEs will be summarized overall, by system organ class, and by preferred term. AESIs will be summarized by event type (thromboembolic events and bleeding events). In addition, treatment-emergent AEs will be summarized by severity and by relationship to study drug. Bleeding events reported during the study will be summarized by WHO grade.
Time frame: Screening through Day 90 or End of Study
Change From Baseline TSQM Convenience Domain Score
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Convenience domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
Time frame: Day 90
Change From Baseline TSQM Side Effects Domain Score
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Side Effects domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
Time frame: Day 90
Change From Baseline TSQM Effectiveness Domain Score
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Effectiveness domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
Time frame: Day 90
Change From Baseline TSQM Global Satisfaction Domain Score
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Global Satisfaction domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
Time frame: Day 90
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame: Day 15
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame: Day 30
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame: Day 60
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame: Day 90
| Milestone | Avatrombopag |
|---|---|
| Started | 60 |
| Completed | 57 |
| Not completed | 3 |
Safety and Tolerability of Avatrombopag given for 90 days after stopping eltrombopag or romiplostim The incidence and severity of adverse events (AEs), serious adverse events (SAE) and adverse events of special interest (AESIs) will be summarized for all enrolled subjects using counts and percentages. Treatment-emergent AEs and SAEs will be summarized overall, by system organ class, and by preferred term. AESIs will be summarized by event type (thromboembolic events and bleeding events). In addition, treatment-emergent AEs will be summarized by severity and by relationship to study drug. Bleeding events reported during the study will be summarized by WHO grade.
| Participants | Avatrombopag |
|---|---|
| TEAEs | 35 |
| SAEs | 6 |
| AESIs | 1 |
| Related TEAEs | 15 |
| Severe TEAEs | 8 |
| TEAEs leading to study drug discontinuation | 2 |
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Convenience domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
| Mean difference in convenience score | Avatrombopag |
|---|---|
| Change From Baseline TSQM Convenience Domain Score | 13.5 (6.9 to 20.1) |
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Side Effects domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
| Mean difference in side effects score | Avatrombopag |
|---|---|
| Change From Baseline TSQM Side Effects Domain Score | 8.3 (2.1 to 14.4) |
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Effectiveness domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
| Mean difference in effectiveness score | Avatrombopag |
|---|---|
| Change From Baseline TSQM Effectiveness Domain Score | 14.4 (7.0 to 21.8) |
Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Global Satisfaction domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.
| Mean difference in global satisfaction | Avatrombopag |
|---|---|
| Change From Baseline TSQM Global Satisfaction Domain Score | 14.2 (8.8 to 19.5) |
| Participants | Avatrombopag |
|---|---|
| Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L | 19 |
| Participants | Avatrombopag |
|---|---|
| Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L | 33 |
| Participants | Avatrombopag |
|---|---|
| Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L | 36 |
| Participants | Avatrombopag |
|---|---|
| Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L | 33 |
Collected over 90 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avatrombopag | 1/60 (1.7%) | 6/60 (10%) | 34/60 (56.7%) |
| Event | Avatrombopag |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/60 |
| Rectal HaemorrhageGastrointestinal disorders | 1/60 |
| Sudden DeathGeneral disorders | 1/60 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/60 |
| NephrolithiasisRenal and urinary disorders | 1/60 |
| Event | Avatrombopag |
|---|---|
| HeadacheNervous system disorders | 8/60 |
| ContusionInjury, poisoning and procedural complications | 7/60 |
| Oedema PeripheralGeneral disorders | 4/60 |
| COVID-19Infections and infestations | 3/60 |
| DizzinessEar and labyrinth disorders | 3/60 |
| FatigueGeneral disorders | 3/60 |
| Peripheral SwellingGeneral disorders | 3/60 |
| ConstipationGastrointestinal disorders | 2/60 |
| DiarrhoeaGastrointestinal disorders | 2/60 |
| NauseaGastrointestinal disorders | 2/60 |
| Age, Continuous(years) | Avatrombopag |
|---|---|
| Mean | 58.0 ± 21.7 |
| Sex: Female, Male(Participants) | Avatrombopag |
|---|---|
| Female | 37 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | Avatrombopag |
|---|---|
| Hispanic or Latino | 13 |
| Not Hispanic or Latino | 46 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Avatrombopag |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 5 |
| White | 43 |
| More than one race | 1 |
| Unknown or Not Reported | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Jan 2024, 33 months.
Results were first posted in Jan 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag
Purpura, Thrombocytopenic, Idiopathic →